medigraphic.com
ISSN 2448-8747 (Impreso)
Publicación cuatrimestral editada por la Secretaría de Salud Jalisco

2018, Número Esp

<< Anterior Siguiente >>

Sal Jal 2018; 5 (Esp)


Vacunas contra el Virus del Dengue, Chikungunya, Zika y Mayaro

Palomares-Marín J, Rodríguez-Preciado SY, Hernández-Andrade L, Hernández-Cañaveral II

Idioma: Español
Referencias bibliográficas: 42
Paginas: 109-115
Archivo PDF: 312.91 Kb.


FRAGMENTO

Virus del Dengue

El virus del dengue produce la enfermada viral más frecuente trasmitida por un mosquito, producida por 4 serogrupos diferentes, pero antigénicamente relacionados (DENV1, 2 3, y 4). La respuesta inmune juega un papel central en la protección y patogénesis de la enfermedad, mientras la infección con un serotipo genera protección contra el mismo serotipo, la infección subsecuente con un serotipo diferente incrementa el riesgo de formas severas. Se estima que cada año ocurren alrededor de 500,000 formas severas de dengue, con un minino de 20,000 muertes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, et al. Dengue: a continuing global threat. Nat Rev Microbiol [Internet]. 2010 Dec 1;8:S7. Available from: http://dx.doi. org/10.1038/nrmicro2460

  2. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol [Internet]. 2013;158(7):1445–59. Available from: https://doi.org/10.1007/s00705-013-1645-3

  3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature [Internet]. 2013 Apr 7;496:504. Available from: http:// dx.doi.org/10.1038/nature12060

  4. Cedillo-Barrón L, García-Cordero J, Bustos-Arriaga J, León-Juárez M, Gutiérrez-Castañeda B. Antibody response to dengue virus. Microbes Infect [Internet]. 2014;16(9):711– 20. Available from: http://www.sciencedirect.com/science/ article/pii/S1286457914000987

  5. de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WMPB, Kraus A, et al. In-Depth Analysis of the Antibody Response of Individuals Exposed to Primary Dengue Virus Infection. PLoS Negl Trop Dis [Internet]. 2011 Jun 21;5(6):e1188. Available from: https://doi.org/10.1371/journal.pntd.0001188

  6. Capeding MR, Tran NH, Hadinegoro SRS, Ismail HIHJM, Chotpitayasunondh T, Chua MN, et al. Clinical effi cacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet [Internet]. 2018 Apr 16;384(9951):1358–65. Available from: http://dx.doi.org/10.1016/S0140-6736(14)61060-6

  7. Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, et al. Effi cacy of a Tetravalent Dengue Vaccine in Children in Latin America. N Engl J Med [Internet]. 2014 Nov 3;372(2):113–23. Available from: https://doi.org/10.1056/ NEJMoa1411037

  8. Vicente CR, Herbinger K-H, Fröschl G, Malta Romano C, de Souza Areias Cabidelle A, Cerutti Junior C. Serotype infl uences on dengue severity: a cross-sectional study on 485 confi rmed dengue cases in Vitória, Brazil. BMC Infect Dis [Internet]. 2016;16(1):320. Available from: https://doi.org/10.1186/s12879- 016-1668-y

  9. Osorio JE, Partidos CD, Wallace D, Stinchcomb DT. Development of a recombinant, chimeric tetravalent dengue vaccine candidate. Vaccine [Internet]. 2015;33(50):7112–20. Available from: http:// www.sciencedirect.com/science/article/pii/S0264410X15016552

  10. Whitehead SS. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine diff erent from the Sanofi -Pasteur CYDTM vaccine? Expert Rev Vaccines [Internet]. 2016 Apr 2;15(4):509–17. Available from: https://doi.org/10.1586/14760584.2016.1115727

  11. L Innis B, H Eckels K. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Vol. 69, Th e American journal of tropical medicine and hygiene. 2004. 1-4 p.

  12. Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis BL, et al. Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Naive Infants. Am J Trop Med Hyg. 2011;85(2).

  13. Aggarwal A, Garg N. Newer vaccines against mosquito-borne diseases. Indian J Pediatr. 2017;1–7.

  14. Kantor IN. Dengue, zika, chikungunya and the development of vaccines. Medicina (B Aires). 2018;78(1):23–8.

  15. Ramsauer K, Tangy F. Chikungunya Virus Vaccines: Viral Vector–Based Approaches. J Infect Dis [Internet]. 2016 Dec 15;214(suppl_5):S500–5. Available from: http://dx.doi. org/10.1093/infdis/jiw369

  16. Erasmus JH, Rossi SL, Weaver SC. Development of Vaccines for Chikungunya Fever. J Infect Dis [Internet]. 2016 Dec 15;214(suppl_5):S488–96. Available from: http://dx.doi. org/10.1093/infdis/jiw271

  17. Silva JVJ, Lopes TRR, Oliveira-Filho EF de, Oliveira RAS, Durães- Carvalho R, Gil LHVG. Current status, challenges and perspectives in the development of vaccines against yellow fever, dengue, Zika and chikungunya viruses. Acta Trop [Internet]. 2018;182:257–63. Available from: http://www.sciencedirect.com/science/article/ pii/S0001706X17314444

  18. Rezza G. Do we need a vaccine against chikungunya? Pathog Glob Health [Internet]. 2015 Jun 1;109(4):170–3. Available from: https://doi.org/10.1179/2047773215Y.0000000017

  19. Ahola T, Couderc T, Ng LFP, Hallengärd D, Powers A, Lecuit M, et al. Th erapeutics and Vaccines Against Chikungunya Virus. Vector-Borne Zoonotic Dis [Internet]. 2015 Apr 1;15(4):250–7. Available from: https://doi.org/10.1089/vbz.2014.1681

  20. Dick GWA, Kitchen SF, Haddow AJ. Zika Virus (I). Isolations and serological specifi city. Trans R Soc Trop Med Hyg [Internet]. 1952;46(5):509–20. Available from: http://www.sciencedirect. com/science/article/pii/0035920352900424

  21. Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika Virus. N Engl J Med [Internet]. 2016 Mar 30;374(16):1552–63. Available from: https://doi.org/10.1056/NEJMra1602113

  22. Darrigo LG, de Sant’Anna Carvalho AM, Machado CM. Chikungunya, Dengue, and Zika in Immunocompromised Hosts. Curr Infect Dis Rep [Internet]. 2018 Mar 17;20(4):5. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857271/

  23. Durbin AP, Whitehead SS. Zika Vaccines: Role for Controlled Human Infection. J Infect Dis [Internet]. 2017 Dec 16;216(suppl_10):S971–5. Available from: http://dx.doi. org/10.1093/infdis/jix491

  24. Casos Confi rmados de Infección por Virus Zika 2018 [Internet]. Secretaria de Salud, Dirección General de Epidemiología. 2018 [cited 2018 Mar 28]. Available from: https://www.gob.mx/ salud/documentos/casos-confi rmados-de-infeccion-por-viruszika- 2018

  25. Blackman MA, Kim I-J, Lin J-S, Th omas SJ. Challenges of Vaccine Development for Zika Virus. Viral Immunol [Internet]. 2017 Dec 11;31(2):117–23. Available from: https://doi.org/10.1089/ vim.2017.0145

  26. Singh RK, Dhama K, Karthik K, Tiwari R, Khandia R, Munjal A, et al. Advances in Diagnosis, Surveillance, and Monitoring of Zika Virus: An Update. Front Microbiol [Internet]. 2017 Jan 19;8:2677. Available from: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC5780406/

  27. Poland GA, Kennedy RB, Ovsyannikova IG, Palacios R, Ho PL, Kalil J. Development of vaccines against Zika virus. Lancet Infect Dis [Internet]. 2018 Apr 16; Available from: http://dx.doi. org/10.1016/S1473-3099(18)30063-X

  28. Lazear HM, Diamond MS. Zika Virus: New Clinical Syndromes and Its Emergence in the Western Hemisphere. Pierson TC, editor. J Virol [Internet]. 2016 May 15;90(10):4864–75. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859708/

  29. Abbink P, Larocca RA, De La Barrera RA, Bricault CA, Moseley ET, Boyd M, et al. Protective effi cacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science (80- ) [Internet]. 2016 Sep 9;353(6304):1129 LP-1132. Available from: http://science.sciencemag.org/content/353/6304/1129.abstract

  30. Larocca RA, Abbink P, Peron JPS, de A. Zanotto PM, Iampietro MJ, Badamchi-Zadeh A, et al. Vaccine protection against Zika virus from Brazil. Nature [Internet]. 2016 Jun 28;536:474. Available from: http://dx.doi.org/10.1038/nature18952

  31. Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, et al. Zika virus protection by a single low-dose nucleosidemodifi ed mRNA vaccination. Nature [Internet]. 2017 Feb 2;543:248. Available from: http://dx.doi.org/10.1038/nature21428

  32. Kim E, Erdos G, Huang S, Kenniston T, Falo Jr. LD, Gambotto A. Preventative Vaccines for Zika Virus Outbreak: Preliminary Evaluation. EBioMedicine [Internet]. 2018 Apr 16;13:315–20. Available from: http://dx.doi.org/10.1016/j.ebiom.2016.09.028

  33. Figueiredo MLG de, Figueiredo LTM. Emerging alphaviruses in the Americas: Chikungunya and Mayaro. Vol. 47, Revista da Sociedade Brasileira de Medicina Tropical . scielo ; 2014. p. 677– 83.

  34. Mackay IM, Arden KE. Mayaro virus: a forest virus primed for a trip to the city? Microbes Infect [Internet]. 2016;18(12):724–34. Available from: http://www.sciencedirect.com/science/article/ pii/S1286457916301666

  35. Hotez PJ, Murray KO. Dengue, West Nile virus, chikungunya, Zika—and now Mayaro? PLoS Negl Trop Dis [Internet]. 2017 Aug 31;11(8):e0005462. Available from: https://doi.org/10.1371/ journal.pntd.0005462

  36. García-Rejón J. Del virus Mayaro y su probable entrada a México y su impacto en la Península Yucatán. Cienc Y HUMANISMO EN LA SALUD. 2017;3(3):1–3.

  37. Weise WJ, Hermance ME, Forrester N, Adams AP, Langsjoen R, Gorchakov R, et al. A Novel Live-Attenuated Vaccine Candidate for Mayaro Fever. PLoS Negl Trop Dis [Internet]. 2014 Aug 7;8(8):e2969. Available from: https://doi.org/10.1371/journal. pntd.0002969

  38. Carvalho CAM, Sousa IP, Silva JL, Oliveira AC, Gonçalves RB, Gomes AMO. Inhibition of Mayaro virus infection by bovine lactoferrin. Virology [Internet]. 2014;452–453:297–302. Available from: http://www.sciencedirect.com/science/article/pii/ S004268221400035X

  39. Esposito DLA, Fonseca BAL da. Will Mayaro virus be responsible for the next outbreak of an arthropod-borne virus in Brazil? Brazilian J Infect Dis [Internet]. 2017;21(5):540–4. Available from: http://www.sciencedirect.com/science/article/pii/ S1413867017301630

  40. Mavian C, Rife BD, Dollar JJ, Cella E, Ciccozzi M, Prosperi MCF, et al. Emergence of recombinant Mayaro virus strains from the Amazon basin. Sci Rep [Internet]. 2017;7(1):8718. Available from: http://europepmc.org/articles/PMC5562835

  41. Cárdenas-Marrufo MF, Pech-Sosa N, Arias-León JJ. Fiebre Mayaro: Enfermedad emergente al acecho. Cienc Y HUMANISMO EN LA SALUD. 2017;3(3):32–40.

  42. Terzian ACB, Auguste AJ, Vedovello D, Ferreira MU, da Silva- Nunes M, Sperança MA, et al. Isolation and Characterization of Mayaro Virus from a Human in Acre, Brazil. Am J Trop Med Hyg. 2015;92(2).




2020     |     www.medigraphic.com